Active — Not RecruitingPhase 4

Efficacy of Donepezil in Patients With Chronic Tinnitus

Brazil70 participantsStarted 2021-11-19

Plain-language summary

This study is a prospective, placebo-controlled, randomized, double-blind clinical trial, including 70 patients with chronic sensorineural tinnitus, divided into placebo and treatment groups. Participants received donepezil for 3 months, starting with 5 mg daily for the first month and 10 mg daily for the following two months.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patients with chronic sensorineural tinnitus type Exclusion Criteria: * pregnancy, arrhythmia, donepezil allergy, yelow dye allergy, otitis or any ear inflamatory diseases, patients taking any medication for dementia, convulsive diseases, asthma, patients taking any of these medications: carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampicin, ketoconazole, quinidine.

What they're measuring

tinnitus improvement

Timeframe: 3 months

Trial details

NCT IDNCT07153991

SponsorUniversity of Sao Paulo

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-12-09

View on ClinicalTrials.gov More Tinnitus trials